# Trade Mark Journal No.2025/029 18 July 2025

## UK00004232695 11 July 2025 (5,42)

CHEMRNA

International priority date claimed: 14 January 2025 (United States of America) (98960020)

Class 5
  Pharmaceuticals; medical preparations; vaccines; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines and medical therapeutics for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; vaccines for human use; nutritional and dietary supplements; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes.
Class 42
  Product research, design and development services; Research, design and development of pharmaceuticals; Research, design and development of medical preparations; Research, design and development of medical technology; scientific and medical research; research and development in the field of therapeutics; research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; development of pharmaceutical preparations, vaccines and medicines; clinical studies; drug development and discovery; medical research for development of therapeutic modalities for treatment of diseases; assays and reagents for use in scientific and biomedical research; research and development of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development of therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; preclinical and clinical development of therapeutic products; information, consultancy and advisory services in relation to all of the above.

Convergence Bio, Inc.

Representative: CMS Cameron McKenna Nabarro Olswang LLP